Former NIH Aging Institute Neuroscience Chief Eliezer Masliah Passes 30 Retractions

Photo: Logan Gutierrez / Unsplash

Two more journals have pulled papers from the former NIA neuroscience director, bringing his total to 32, with 15 of those retractions coming this year.

Background

Eliezer Masliah ran the Division of Neuroscience at the National Institute on Aging (NIA) from 2016 to 2024, a post that put him over a research portfolio of nearly $2.6 billion a year [1]. Before joining the National Institutes of Health (NIH), he was a professor at the University of California, San Diego. He has coauthored more than 800 papers, most of them on alpha-synuclein, the protein at the center of Parkinson's disease research, and Web of Science counts more than 147,000 citations of his work [1].

In 2024, a Science investigation by Charles Piller reported signs of data and image manipulation in more than 130 of Masliah's papers [1]. The reporting drew on a roughly 300-page dossier compiled by four image analysts and researchers: Matthew Schrag of Vanderbilt, Mu Yang of Columbia, independent forensic image analyst Kevin Patrick, and Elizabeth Bik. The dossier flagged suspect images in 132 papers, with problems reaching back to the late 1990s [1].

Separately, NIH announced on September 26, 2024, that it had found Masliah committed research misconduct, describing "falsification and/or fabrication" involving reused and relabeled figure panels that were presented as different experimental results in two publications [2]. NIH said it had opened its review in May 2023 after receiving allegations from the HHS Office of Research Integrity, concluded the investigation on September 15, 2024, and that Masliah was no longer serving as NIA neuroscience director [2].

What Happened

According to Retraction Watch, Masliah now has 32 retractions, 15 of them in 2026 [1]. The retracted papers so far span 2008 to 2022 [1].

The two most recent are both in Springer Nature journals. On October 5, 2026, Nature Communications retracted a 2018 paper reporting that the enzyme LRRK2 regulates the spread of alpha-synuclein through phosphorylation of a protein called RAB35 [3]. The notice cites an image in one figure that looks highly similar to an image in another, apparent overlaps between panels in two other figures, and further irregularities in a fourth. The authors told the journal that their quantitative analyses came from complete image datasets and that source data were retained, but they accepted that the integrity of the published figures could not be assured [3]. All living authors agreed to the retraction; one coauthor, Edward Rockenstein, is deceased [3].

The paper's corresponding author, Seung-Jae Lee of Seoul National University, told Retraction Watch that the publisher contacted him in 2024 about concerns raised on PubPeer [1]. He said Masliah could not retrieve some raw images because the facility had closed, that Masliah had supplied representative images and graphs from the mouse studies, and that Lee's team performed the other experiments. Lee said he regrets the errors but does not believe they undermine the paper's central claim [1].

On November 6, 2026, Cell Death & Disease retracted a 2011 paper on whether modulating aberrant CDK5 signaling could rescue impaired neurogenesis in Alzheimer's disease models [4]. The editors pointed to a merged microscopy image that did not fully match its component channels and contained a duplicated pattern, apparent overlap between two other panels, and supplementary panels showing highly similar artifacts at different brightness. They said they "no longer have confidence in the presented data" [4]. Masliah and coauthor L. Crews disagreed with the retraction; two other authors did not respond to the editors [4].

The Allegations and the Response

Masliah declined to comment to Retraction Watch on the concerns or the retractions [1]. NIH did not respond to Retraction Watch's request for comment [1].

The NIH misconduct finding remains limited to two publications [2]. Schrag told Retraction Watch that the broader set of problems includes reused images, altered channel intensities and spliced western blot lanes, and that some of the corrections Masliah issued over the years introduced new problems [1]. Those are the sleuths' assessments; NIH has not said whether it will examine the dossier's remaining allegations, and Piller told Retraction Watch the agency seemed overwhelmed [1]. NIH has said that any allegations about Masliah's NIH-funded extramural research before he joined the agency would be referred to the HHS Office of Research Integrity [2].

Some of Masliah's work was cited in studies of Cerebrolysin, a peptide mixture that is not approved by the US Food and Drug Administration [1].

What Comes Next

With more than 130 papers flagged and 32 retracted, the arithmetic leaves plenty of room. Piller told Retraction Watch he expects more retractions given the volume of papers involved [1]. Journals have so far acted paper by paper. Whether NIH or the Office of Research Integrity opens any wider inquiry is the larger open question, and neither has said so publicly.

This article is for informational purposes only and is not medical advice; readers with health questions should consult their clinician.

References

  1. Pathak M. Former NIH neuroscientist passes 30 retractions. Retraction Watch. November 17, 2026. https://retractionwatch.com/2026/11/17/eliezer-masliah-nih-aging-institute-image-manipulation-retractions/

  2. National Institutes of Health. Statement by NIH on Research Misconduct Findings. NIH News Releases. September 26, 2024. https://www.nih.gov/news-events/news-releases/statement-nih-research-misconduct-findings

  3. Retraction Note: LRRK2 kinase regulates α-synuclein propagation via RAB35 phosphorylation. Nature Communications. 2026;17:10492. October 5, 2026. https://www.nature.com/articles/s41467-026-77966-3

  4. Retraction Note: Modulation of aberrant CDK5 signaling rescues impaired neurogenesis in models of Alzheimer's disease. Cell Death & Disease. 2026;17:945. November 6, 2026. https://www.nature.com/articles/s41419-026-09413-6

Emma Nguyễn

While you argue with patients over TikTok liver detoxes, I investigate the the biology behind the sensationalism. At Culture Desk Rx, documenting where clinical reality collides with the wellness industry is my passion. I left Silicon Valley for Austin, Texas, where I willingly infiltrate unhinged wellness retreats to see if a "higher consciousness" actually exists, or if it's just severe dehydration. I also write the occasional joke. Deal with it.

I write about the parts of medicine nobody puts in the brochure. Who actually staffs the hospital, and who gets left out. Why safety-net hospitals run on doctors trained overseas, and what those doctors give up to work here. Who gets into medical school, and who decides.

Tell me what the medical establishment is ignoring, or just send me the wildest pseudo-science your patients have tried this week. My inbox is open.

Previous
Previous

Boston Scientific’s Obsidio Embolic Posts Clean 30-Day Results in Company-Sponsored Registry

Next
Next

FDA Approves Giredestrant Plus Everolimus for ESR1-Mutated Advanced Breast Cancer